Unleashing the power of next generation ADC cancer treatments

View Pipeline

Pipeline

AmMax Bio is developing a robust oncology pipeline of Antibody Drug Conjugates (ADCs), with its lead program, AMB-104, incorporating clinically validated components and supported by compelling preclinical data.

AMB
104 VIEW

Dr. Elie Traer, MD, PhD, Associate Professor of Medicine, OHSU

discusses the unmet needs of AML and the clinical utility of targeting monocytic AML cells with AmMax's ADC AMB-104.

Latest News

All News
Mar 11, 2025

AmMax Bio Announces Presentation at BIO-Europe Spring 2025

 Read More Jan 27, 2025

AmMax Bio Announces First Patient Dosed in Phase 2a Study Evaluating AMB-066 in Patients with Colorectal Cancer Minimal Residual Disease

 Read More Dec 10, 2024

AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

 Read More
All News